Sourbier Carole, Massfelder Thierry
INSERM U727, Section of Renal Pharmacology and Physiopathology, School of Medicine, University Louis Pasteur, 67085 Strasbourg, France.
Cancer Lett. 2006 Aug 28;240(2):170-82. doi: 10.1016/j.canlet.2005.08.020. Epub 2005 Oct 11.
Parathyroid hormone-related protein (PTHrP), a polyprotein discovered in 1987, plays crucial roles not only in development and in various physiological events associated with normal life, but also in a number of pathological conditions such as cancer. PTHrP appears as the major causative agent in humoral hypercalcemia of malignancy (HHM) associated to a broad range of tumors. However, this is only one aspect of the multiple facets of PTHrP in cancer biology. Indeed, the complex growth factor-like properties of PTHrP has shed new light onto potential roles of this peptide in the regulation of tumor growth and invasion. Initial studies in breast, prostate and lung cancer and recent results in renal cell carcinoma (RCC) suggest such roles and highlight the therapeutic potential of PTHrP-targeting strategies in human cancer including RCC. In this review, the role of PTHrP in RCC tumorigenesis and its potential as a therapeutic target will be discussed.
甲状旁腺激素相关蛋白(PTHrP)是1987年发现的一种多蛋白,不仅在发育以及与正常生命相关的各种生理活动中发挥关键作用,而且在许多病理状况如癌症中也起作用。PTHrP似乎是与多种肿瘤相关的恶性肿瘤体液性高钙血症(HHM)的主要致病因素。然而,这只是PTHrP在癌症生物学中多方面作用的一个方面。事实上,PTHrP复杂的生长因子样特性为该肽在肿瘤生长和侵袭调节中的潜在作用带来了新的认识。对乳腺癌、前列腺癌和肺癌的初步研究以及肾细胞癌(RCC)的最新研究结果表明了这些作用,并突出了靶向PTHrP策略在包括RCC在内的人类癌症中的治疗潜力。在本综述中,将讨论PTHrP在RCC肿瘤发生中的作用及其作为治疗靶点的潜力。